Oxford Immunotec Global PLC (OXFD) Reaches New 12-Month Low After Insider Selling

Oxford Immunotec Global PLC (NASDAQ:OXFD)’s share price reached a new 52-week low during trading on Thursday following insider selling activity. The company traded as low as $12.48 and last traded at $0.00, with a volume of shares changing hands. Specifically, COO Peter Edwardson sold 22,371 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $17.70, for a total value of $395,966.70. Following the transaction, the chief operating officer now owns 102,644 shares in the company, valued at $1,816,798.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the transaction, the director now owns 17,778 shares in the company, valued at approximately $237,336.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,110 shares of company stock worth $1,563,564. 8.11% of the stock is currently owned by company insiders.

Several research firms have weighed in on OXFD. Piper Jaffray Companies lowered their price objective on shares of Oxford Immunotec Global PLC from $26.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday. Cowen and Company lowered their price objective on shares of Oxford Immunotec Global PLC from $22.00 to $19.00 and set an “outperform” rating on the stock in a research report on Thursday, August 17th. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Robert W. Baird reiterated a “buy” rating and set a $20.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Wednesday. Finally, ValuEngine cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $19.75.

The company has a quick ratio of 2.51, a current ratio of 4.72 and a debt-to-equity ratio of 0.38.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). The firm had revenue of $26.10 million during the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 38.42% and a negative net margin of 45.74%. The firm’s revenue was up 35.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) EPS. research analysts forecast that Oxford Immunotec Global PLC will post -2.11 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. American International Group Inc. increased its position in Oxford Immunotec Global PLC by 7.1% during the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after purchasing an additional 904 shares during the period. Nationwide Fund Advisors increased its position in Oxford Immunotec Global PLC by 1.9% during the 1st quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after purchasing an additional 254 shares during the period. Parkwood LLC increased its position in Oxford Immunotec Global PLC by 12.9% during the 2nd quarter. Parkwood LLC now owns 12,799 shares of the company’s stock worth $215,000 after purchasing an additional 1,465 shares during the period. Voya Investment Management LLC increased its position in Oxford Immunotec Global PLC by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after purchasing an additional 1,845 shares during the period. Finally, Alliancebernstein L.P. acquired a new position in Oxford Immunotec Global PLC during the 2nd quarter worth approximately $247,000. 79.21% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Oxford Immunotec Global PLC (OXFD) Reaches New 12-Month Low After Insider Selling” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.com-unik.info/2017/11/04/oxford-immunotec-global-plc-oxfd-reaches-new-12-month-low-after-insider-selling.html.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

What are top analysts saying about Oxford Immunotec Global PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oxford Immunotec Global PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit